PIPGEN - PhD Project 13: To identify PI3K vascular-related therapies which enhance immunoregulation flux.
Research · Josep Carreras Leukaemia Research Institute. Spain > Badalona
RESEARCH PROFILE: First Stage Researcher (R1)
APPLICATION DEADLINE: 27 June 2021
EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020
MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 955534
 First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.
PhD Project details
Vascular growth abnormalities are a hallmark of Pik3ca-related vascular tumours. Drugs targeting PI3Ka in tumours have proven to inhibit vessel growth, enhance hypoxia and impair antitumor immunity. ESR13 will take advantage of a collection of mouse models that allow to express diferent variants of Pik3ca oncogenic mutations (from low to high PI3K signalling) in endothelial cells, to study cell growth and immune infiltration. Vascular growth in the aforementioned mice will be followed by histological, FACS and molecular characterization by RNAseq of endothelial cells and immune populations. Upon identifying, possible targeting approaches, ESR13 will apply combinatory therapies to target vascular and immune cells.
Host: Institut de Recerca contra la Leucèmia Josep Carreras (JOSEP CARRERAS INSTITUTE), Spain.
Supervisor: Dr. Mariona Graupera.
Doctoral programme: University of Barcelona.
Envisioned secondments: Inserm, UCL.